Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
Publication
, Journal Article
Wu, Y; Amonkar, MM; Sherrill, BH; O'Shaughnessy, J; Ellis, C; Baselga, J; Blackwell, KL; Burstein, HJ
Published in: Ann Oncol
June 1, 2019
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 1, 2019
Volume
30
Issue
6
Start / End Page
1019
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wu, Y., Amonkar, M. M., Sherrill, B. H., O’Shaughnessy, J., Ellis, C., Baselga, J., … Burstein, H. J. (2019). Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol, 30(6), 1019. https://doi.org/10.1093/annonc/mdy531
Wu, Y., M. M. Amonkar, B. H. Sherrill, J. O’Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell, and H. J. Burstein. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.” Ann Oncol 30, no. 6 (June 1, 2019): 1019. https://doi.org/10.1093/annonc/mdy531.
Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 Jun 1;30(6):1019.
Wu, Y., et al. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.” Ann Oncol, vol. 30, no. 6, June 2019, p. 1019. Pubmed, doi:10.1093/annonc/mdy531.
Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 Jun 1;30(6):1019.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
June 1, 2019
Volume
30
Issue
6
Start / End Page
1019
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis